Evaxion AS Stock Price, News & Analysis

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced its participation in multiple scientific and investor conferences across the US, Europe, and Asia during H2 2025.

The company's Chief Scientific Officer and interim CEO Birgitte Rønø highlighted that their two-year clinical data for the personalized cancer vaccine EVX-01 has been selected for oral presentation at the ESMO congress in October. The conference schedule includes prestigious events such as the Vaccine Congress in Kyoto, HC Wainwright Global Investment Conference in New York, and the World Vaccine Congress Europe in Amsterdam.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, reported Q2 2025 financial results and business updates. Key highlights include completion of EVX-01 phase 2 trial treatments, with full two-year clinical efficacy data to be presented at ESMO Congress in October 2025. The company received recognition through a Gates Foundation grant for polio vaccine development and expanded its pipeline with EVX-B4 for Group A Streptococcus.

Financial position improved with $14.7 million in cash as of June 30, 2025, sufficient until mid-2026. The company converted €3.5 million of EIB debt to equity at a 89% premium. Q2 2025 resulted in a net loss of $4.8 million ($0.02 per share), compared to $6.2 million loss in Q2 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q2 2025 financial results and business update for August 14, 2025, before Nasdaq CM market opening.

The company will host a conference call and webcast at 14:30 CET/08:30 EST on the same day, where Executive Management will present the results and take questions. Participants must pre-register to receive dial-in details and a PIN code. The webcast recording will be available on Evaxion's website after the event.

Evaxion (NASDAQ: EVAX) announced it will present two-year clinical efficacy data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma, at the ESMO Congress 2025 in Berlin. The trial combines EVX-01 with MSD's KEYTRUDA® and has shown promising results, with interim one-year data demonstrating a 69% Overall Response Rate and tumor reduction in 15 out of 16 patients.

The presentation will take place on October 17, 2025, featuring data that validates their AI-Immunology™ platform's predictions, which showed significant correlation (p=0.00013) with immune responses to the personalized vaccine's neoantigens. Each patient in the trial received a unique vaccine designed based on their individual biology.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has finalized a significant debt-to-equity conversion agreement with the European Investment Bank (EIB). Under the agreement, EIB will convert €3.5 million of its existing €7 million loan into equity through warrant purchases at $4.87 per share, representing an 89% premium to the previous day's closing price.

The strategic transaction immediately strengthens Evaxion's equity position by $4.1 million (€3.5 million), while significantly reducing the company's debt burden. This restructuring is expected to enhance Evaxion's financial flexibility and improve cash flow, marking a positive development in the company's financial management strategy.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced significant changes to its executive management team. CEO Christian Kanstrup has stepped down, with Chief Scientific Officer Dr. Birgitte Rønø appointed as interim CEO while the company searches for a permanent replacement.

The company has also appointed Thomas Schmidt as permanent Chief Financial Officer, following his interim role since November 2024. These management changes are part of Evaxion's strategy to optimize value from its proprietary AI-Immunology™ platform and pipeline developed over 17 years.

The Board of Directors is conducting a search for a new permanent CEO with strong business development focus, proven transformational leadership, and strategic partnership capabilities. Dr. Rønø, who has been with Evaxion since 2017 and joined Executive Management in 2021, will ensure leadership continuity during the transition period.

Evaxion (NASDAQ: EVAX) has announced the addition of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS) to its R&D pipeline. Initial computational analysis shows that the company's AI-Immunology™ platform can successfully identify novel vaccine targets to combat GAS, which affects hundreds of millions globally each year.

The bacteria can cause severe complications including rheumatic heart disease, necrotizing fasciitis, strep throat, and scarlet fever. The development of EVX-B4 represents a significant milestone in Evaxion's 2025 objectives, bringing their pipeline to eight vaccine candidates - five for infectious diseases and three for cancer.

Evaxion (NASDAQ: EVAX) has received a grant from the Gates Foundation to develop a new polio vaccine using its AI-Immunology™ platform. The project aims to help eradicate polio globally by designing a novel vaccine construct that eliminates the need for live viruses in production. Despite existing vaccines, polio remains a threat with potential for global resurgence. Evaxion's AI platform will identify and combine various antigens to combat the virus, creating new antigen constructs for selection and validation. CEO Christian Kanstrup highlighted that the grant enables platform validation without additional operational costs. The innovative approach seeks to overcome limitations of current vaccines, which use inactivated or attenuated viruses, by developing a safer and more effective alternative.

Evaxion (NASDAQ: EVAX) reported Q1 2025 financial results and provided business updates. Key highlights include: EVX-01 phase 2 trial progression with 80% of vaccine targets triggering tumor-specific immune responses, significantly higher than comparable vaccines. The company's cash position improved to $17.8 million as of March 31, 2025, from $6.0 million in December 2024, extending runway to mid-2026. Q1 2025 showed a net loss of $1.6 million ($0.01 per share) compared to net income of $1.2 million in Q1 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year. The company expects potential value catalysts in H2 2025, including EVX-01 two-year data readout and possible MSD option exercise for EVX-B2 and EVX-B3 programs. Evaxion is targeting at least two new partnership agreements in 2025, though market conditions may impact timing.